Online citations, reference lists, and bibliographies.

Apoptotic Signaling Induced By Immunomodulatory Thalidomide Analogs In Human Multiple Myeloma Cells: Therapeutic Implications.

Nicholas Mitsiades, Constantine S. Mitsiades, Vassiliki Poulaki, Dharminder Chauhan, Paul G Richardson, Teru Hideshima, Nikhil C. Munshi, Steven P Treon, Kenneth C. Anderson
Published 2002 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Thalidomide (Thal) achieves responses even in the setting of refractory multiple myeloma (MM). Although increased angiogenesis in MM bone marrow and the antiangiogenic effect of Thal formed the empiric basis for its use in MM, we have shown that Thal and its immunomodulatory analogs (IMiDs) directly induce apoptosis or growth arrest of MM cells, alter adhesion of MM cells to bone marrow stromal cells, inhibit the production of cytokines (interleukin-6 and vascular endothelial growth factor) in bone marrow, and stimulate natural killer cell anti-MM immunity. In the present study, we demonstrate that the IMiDs trigger activation of caspase-8, enhance MM cell sensitivity to Fas-induced apoptosis, and down-regulate nuclear factor (NF)-kappa B activity as well as expression of cellular inhibitor of apoptosis protein-2 and FLICE inhibitory protein. IMiDs also block the stimulatory effect of insulinlike growth factor-1 on NF-kappa B activity and potentiate the activity of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L), dexamethasone, and proteasome inhibitor (PS-341) therapy. These studies both delineate the mechanism of action of IMiDs against MM cells in vitro and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM.
This paper references
10.1016/S0006-2952(99)00388-3
Mechanism of action in thalidomide teratogenesis.
Trent D. Stephens (2000)
10.1182/blood.V99.6.2162
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Nicholas Mitsiades (2002)
10.1002/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W
Hypothesis: thalidomide embryopathy-proposed mechanism of action.
Trent D. Stephens (2000)
Thalidomide: the revival of a drug with therapeutic promise in the treatment of cancer Principles and Practice of Oncology Update Series
P Richardson
10.11501/3184403
Cytokines Prevent Dexamethasone-induced Apoptosis via the Activation of Mitogen-activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways in a New Multiple Myeloma Cell Line
小川 愛 (2001)
10.1126/science.281.5383.1680
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Chuan Ying Wang (1998)
Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway [abstract
S Lentzsch (2000)
10.1182/blood.V96.9.2943
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima (2000)
10.1038/sj.leu.2402295
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta (2001)
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Kai Neben (2000)
Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.
Jayne A. Keifer (2001)
IGF1-induced activation of NF-kB and upregulation of intracellular anti-apoptotic proteins in human multiple myeloma cells: therapeutic implications [abstract
CS Mitsiades (2001)
10.1128/MCB.21.12.3964-3973.2001
NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling
Sebastian Kreuz (2001)
Articles on similar topics can be found in the following Blood collections
(2004)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Laura G. Corral (1999)
10.1006/exer.1997.0292
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
B M Kenyon (1997)
10.1182/blood.V88.6.2250.bloodjournal8862250
Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines.
Patrik Georgii-Hemming (1996)
10.1016/S0037-1963(00)90079-9
Thalidomide for resistant and relapsing myeloma
Raymond Alexanian (2000)
A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).
Paul G Richardson (2001)
10.1074/jbc.C100074200
Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells*
Dharminder Chauhan (2001)
10.1073/pnas.94.19.10057
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.
Zhaofei Chu (1997)
10.1097/00006982-199616030-00022
Thalidomide is an inhibitor of angiogenesis.
Robert J D'Amato (1994)
Lowdose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica
A Palumbo (2002)
10.1056/nejm200003303421313
Thalidomide in multiple myeloma.
Sundararajan Vincent Rajkumar (2000)
10.1182/blood.V98.1.210
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith Davies (2001)
10.2165/00128413-200112940-00034
Low-dose thalidomide plus dexamethasone is effective as salvage therapy for advanced myeloma,
A P Palumbo (2001)
10.1046/j.1432-1327.1998.2540439.x
Apoptosis signaling by death receptors.
Klaus Schulze-Osthoff (1998)
10.1016/S1043-2760(01)00441-6
Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases
Nicholas S Mitsiades (2001)
10.1046/j.1365-2141.1997.592708.x
Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors.
Fan Xu (1997)
IGF- 1-induced activation of NF-kB and upregulation of intracellular anti-apoptotic proteins in human multiple myeloma cells: therapeutic implications [abstract]
Cs Mitsiades (2001)
10.1056/NEJM199911183412102
Antitumor activity of thalidomide in refractory multiple myeloma.
S Singhal (1999)
10.1074/jbc.271.47.30089
Modulation of JunD·AP-1 DNA Binding Activity by AP-1-associated Factor 1 (AF-1)*
C Powers (1996)
10.1038/sj.onc.1204623
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications
Teru Hideshima (2001)
10.1182/blood.v93.9.3044
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.
Rena Feinman (1999)
10.1016/S0002-9440(10)65708-2
Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.
Nicholas S Mitsiades (1998)
Thalidomide: the revival of a drug with therapeutic promise in the treatment of cancer
P Richardson (2001)
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Teru Hideshima (2001)
10.1182/blood.V98.3.795
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Constantine S. Mitsiades (2001)
10.1182/blood.V96.8.2856.h8002856_2856_2861
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.
Ningling Ge (2000)



This paper is referenced by
10.1038/sj.cdd.4401877
NF-κB and IKK as therapeutic targets in cancer
Hyo Jung Kim (2006)
10.1038/s41375-019-0517-6
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Ola Landgren (2019)
10.2147/OTT.S65762
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
Jing Wang (2015)
10.1186/1476-9255-11-23
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism
Srabani Pal (2014)
10.1007/s00262-014-1571-6
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
Brenda De Keersmaecker (2014)
10.1111/j.1365-2141.2012.09120.x
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Merav Leiba (2012)
10.1517/14740338.2011.619975
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
Antonio Palumbo (2012)
10.4049/jimmunol.1002460
Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma
Brigitte Neuber (2011)
10.1002/pros.21488
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Jake Y. Henry (2012)
10.1080/10428190802365033
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation
Owen A. O’Connor (2008)
10.1007/s12185-015-1925-7
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
Haruhito Totani (2015)
10.1634/theoncologist.7-suppl_1-20
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Mohamad A. Hussein (2002)
10.1007/S12445-011-0181-1
Nieuwe behandelingen voor multipel myeloom
N. van de Donk (2011)
10.1517/14728214.2012.713345
Emerging biological insights and novel treatment strategies in multiple myeloma
Massimo Gentile (2012)
10.1159/000257990
Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma
Sarah J. Richardson (2009)
10.2147/BTT.S3088
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
Aldo M Roccaro (2008)
10.18632/oncotarget.24160
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
Takashi Yoshida (2018)
Chapter 7 Induction Therapy in Multiple Myeloma
Sule Mine Bakanay (2013)
10.1007/s10637-006-9025-4
Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
Sujith R Kalmadi (2006)
10.4103/0366-6999.156134
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Shu-kai Qiao (2015)
10.1002/9780470571224.PSE463
In‐Depth Look: Anti‐TNF‐α Therapies
Satadal Chatterjee (2011)
10.2165/11206420-000000000-00000
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Lesley J. Scott (2011)
10.1111/jphp.12072
Carfilzomib: a novel agent for multiple myeloma.
Kimberly A. Redic (2013)
10.1634/theoncologist.2008-0214
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Angelo Delmonte (2009)
10.2217/fon.10.2
Novel therapeutic targets for multiple myeloma.
Anuj Mahindra (2010)
10.1007/s12185-009-0409-z
Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65
Shihui Li (2009)
10.1111/j.1742-4658.2009.07388.x
Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.
Daniela Berg (2009)
10.1016/j.ejmech.2019.01.023
A novel cereblon modulator for targeted protein degradation.
Sung Ah Kim (2019)
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Teru Hideshima (2003)
10.12691/IJHD-1-1A-3
Cereblon and Its Role in the Treatment of Multiple Myeloma by Lenalidomide or Pomalidomide
Ota Fuchs (2014)
10.1634/theoncologist.12-3-281
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
J. Armand (2007)
10.1038/sj.sc.3102115
Thalidomide for acute treatment of neurosarcoidosis
Edward R. Hammond (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar